Aqualung Therapeutics

'First In Human' Antibody Therapy Alleviates Runaway Inflam...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9


TARGETING RUNAWAY INFLAMMATION
Aqualung Therapeutics Overview

Aqualung Therapeutics has developed a novel drug to mitigate the effects of runaway inflammation typically observed in patients with acute respiratory distress syndrome (ARDS), which can be caused by sepsis, trauma, bacterial or viral pneumonia and COVID-19.

Our proprietary drug technology is a monoclonal antibody (ALT-100) that targets and inhibits the function of eNAMPT, a potent immune protein that regulates systemic inflammation and is a key biomarker in ARDS.


TARGETING RUNAWAY INFLAMMATION
Aqualung Therapeutics Overview

Aqualung Therapeutics has developed a novel drug to mitigate the effects of runaway inflammation typically observed in patients with acute respiratory distress syndrome (ARDS), which can be caused by sepsis, trauma, bacterial or viral pneumonia and COVID-19.

Our proprietary drug technology is a monoclonal antibody (ALT-100) that targets and inhibits the function of eNAMPT, a potent immune protein that regulates systemic inflammation and is a key biomarker in ARDS.


TARGETING RUNAWAY INFLAMMATION
No FDA-Approved Therapies for ARDS

ARDS is a highly inflammatory critical illness in which fluid accumulates in the lungs, causing less air to reach the lungs thereby preventing oxygen from reaching the bloodstream and being delivered to vital organs.

ARDS has a variety of causes, including sepsis, trauma, bacterial or viral pneumonia and, more recently, SARS-CoV-2 (COVID-19). It is often fatal, with a 40% mortality rate. The risk of death is higher in the elderly, and patients with other medical illnesses.

Current treatments for ARDS largely consist of supportive care, lower tidal volume (air delivered to the lungs with each breath), and mechanical ventilation, which contributes to ARDS mortality. There are currently no other FDA-approved therapies for ARDS.

With ~500,000 new cases of ARDS in the US annually (pre-COVID pandemic), a safer, more effective therapy is an imperative.


TARGETING RUNAWAY INFLAMMATION
Targeting the Source of Inflammation

After advancing a research program designed to identify genes involved in the staggering mortality of inflammatory disorders such as ARDS, scientists with Aqualung Therapeutics discovered the protein eNAMPT to be responsible for amplified inflammation in these conditions.

Now, Aqualung Therapeutics can target the eNAMPT protein with our proprietary therapeutic drug, ALT-100 mAb, which is designed to address and prevent unchecked inflammation in several inflammatory diseases by binding to and inhibiting the function of eNAMPT.

Our preclinical studies with ALT-100 mAb have demonstrated significant reductions in inflammation and preservation of vital organs, which will lead to shorter ICU hospitalizations and saving lives of those who are diagnosed with ARDS.


TARGETING RUNAWAY INFLAMMATION
Early Successes

Product Development | Aqualung Therapeutics has completed pharmacodynamic, pharmacokinetic and small animal toxicology studies and has additionally completed a formal Type B meeting with the FDA.

Patents & IP | We have been issued method-of-use patents for ARDS and several other indications and have submitted a composition of matter patent which is pending.

Manufacturing Partnerships | We are partnered with Wuxi Biologics, the current manufacturer of 25% of global biologic medicines, to produce our ALT-100 mAb therapy.

Research Validation | Aqualung Therapeutics has received $10 million in grants from the NIH to perform our eNAMPT research and to develop ALT-100 mAb, allowing us to validate our current scientific theses while moving forward with research on additional indications for the ALT-mAb.


TARGETING RUNAWAY INFLAMMATION
Our Story

As a physician scientist with three decades of experience treating ARDS patients, founder Joe GN Garcia, MD, recognized a need for an impactful therapy to reduce the 40% mortality rate of this vexing condition.

As Chief of Pulmonary and Critical Care Medicine at Johns Hopkins University, Dr. Garcia utilized his expertise in genomics-based research to identify a novel protein that is critical to driving inflammation in patients with ARDS and patients placed on a ventilator.

With this knowledge, he founded Aqualung Therapeutics and has now developed a novel and highly effective method (ALT-100 mAb) to dampen inflammation, reduce the time on the ventilator and increase ARDS survival.


TARGETING RUNAWAY INFLAMMATION
Meet The Team

Joe GN Garcia, MD, CEO & Cofounder | Joe is a physician scientist and a world-recognized leader in pulmonary medicine. He has over 600 published manuscripts, is the former chief of critical care at Johns Hopkins and ran the University of Illinois and University of Arizona Health Systems.

Stan Miele, President & CBO | Stan has over 35 years of industry experience and is the former president of Sucampo Pharmaceuticals. He previously worked at Abbott Laboratories and has global development and commercial experience.

Mariam Morris, CPA | Mariam is a seasoned CFO who has been in the pharma biotech space for over 25 years. She initiated and executed two IPOs and brings a strong background in both private and public biotech companies.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.